Conference Coverage
Combination VEGF and Immune Checkpoint Inhibitors as a First-Line Option for Patients With Advanced Hepatocellular Carcinoma
03/25/2025
James Harding, MD, Memorial Sloan Kettering Cancer Center, New York, New York, discusses advantages associated with combining VEGF inhibitors and immune checkpoint inhibition in the first-line setting for patients with advanced hepatocellular carcinoma.
Dr Richard Finn makes the opposing argument here.
Source:
Harding J. Optimal frontline therapy and sequencing in advanced HCC: VEGF inhibition with ICI. Presented at Great Debates in Solid Tumors. March 22-23, 2025; New York, NY.
